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the concomitant administration of ganciclovir in 2 patients.
The median serum creatinine (SCr) (mg/dl, range) prior to,
during, and post-FOS CI were 1.3 (0.7-2.2), 1.15 (0.7-2.0), and
1.9 (0.9-7.1), respectively. In the analysis of individual data,
median net change in SCr was 0.3 mg/dl (range: -0.9 to +5.7)
from the pre- to the post-FOS period, although one patient
developed renal failure shortly before dying of multi-organ
failure, GVHD and persistent CMV disease.
Conclusion: FOS CI permitted the safe administration of
outpatient treatment in patients at high risk for nephrotox-
icity with CMV reactivation and/or disease which, in our
experience, has increased the utility of this drug. Data
regarding comparative efﬁcacy to standard infusion will
require additional study.285
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Background: Romiplostim is a thrombopoietin receptor
agonist utilized in the treatment of pediatric patients with
immune thrombocytopenia. Furthermore, the limited
toxicity of romiplostim makes this an attractive option for
the treatment of post-HSCT immune thrombocytopenia. We
describe a 3-year-old male with X-linked chronic granulo-
matous disease (CGD) treated with unrelated donor HSCT.
His course was complicated by immune dysregulation
manifest as recurrent pleural effusions that improved with
corticosteroids. At 1-year post HSCT, after stopping his cor-
ticosteroids he developed symptomatic thrombocytopenia
and autoimmune hemolytic anemia (AIHA). He was started
on romiplostimwith improvement in his thrombocytopenia.
Methods: A 3-year-old Asian male was diagnosed with
X-CGD. The patient underwent HSCT utilizing a 9/10 HLA
matched unrelated female donor. The preparative regimen
was: busulfan (0.8 mg/kg/dose x 16 doses), cytoxan (50 mg/
kg/dose x 4 doses), ﬂudarabine (30mg/m2) and Campath
(2 mg x 4 doses). Graft-versus-host disease prophylaxis was:
cyclosporine and methotrexate. Post-HSCT he developed
seizures and mucositis. He engrafted on Day +18 with 100%
donor engraftment. On Day +62 and +119 he presented with
symptomatic pleural effusions. Evaluation for infectious
pathogens was negative. On both occasions a response to
corticosteroids was documented. At 1-year post-HSCT as his
corticosteroid taper ﬁnished he developed symptomatic
thrombocytopenia (platelet count 5,000 / uL).
Results: He was treated with intravenous immunoglobulin
and platelet transfusion without signiﬁcant improvement. In
addition to symptomatic thrombocytopenia a warm AIHA
(hemoglobin 5.2 g / dL) emerged. Evaluation for infectious
pathogens was negative. A bone marrow examination
demonstrated a cellular marrow with trilineage hemato-
poiesis, megakaryocytic hypoplasia, and erythroid hyper-
plasia. Cytogenetic evaluation demonstrated a normal male
karyotype and chimerism studies documented 98% donor
engraftment. In order to avoid the toxicity associated with
corticosteroid use romiplostim was started at 5 mcg/kg
subcutaneous each week. Within three 3 weeks of starting
therapy his platelet count was> 50,000 / uL. He continues to
maintain a platelet count > 100,000 / uL while tapering hisromiplostim dose. His hemoglobin also continued to improve
without a need for transfusion support.
Conclusion: To our knowledge, this is the ﬁrst description of a
successful application of romiplostim as initial therapy in a
pediatric patient with immune thrombocytopenia following
matched unrelated donor HSCT for X-linked CGD. We found
that the use of romiplostim to be an effective and safe alter-
native to thepotentialmorbidityandmortality associatedwith
the use of immunosuppressive agents such as corticosteroids.286
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Hematopoietic progenitor stem cell transplantation (HSCT)
has different stages; the presence of anxiety and psycho-
logical disorders is frequently reported. Objective. To assess
and compare the patient’s psychological state before and
after HSCT, evaluating the level of anxiety, emotional in-
dicators and external variables which inﬂuence the psycho-
logical state. Method. First stage, pre- HSCT, 70 patients were
assessed: 26 females and 44 males, from the Oncological,
Hematological and Immunological departments. Age: 6-18
years old, appropriate for tests. Registration: age, gender,
diagnosis, date of diagnosis, hospital stay and family dy-
namics. Standardized psychological tests and semi-struc-
tured interview. Second stage, post- HSCT. Same assessment
but with 18 patients. Results. 70% of patients showed social
concerns. With regards to their family, most of them had at
least 2 emotional indicators. Most patients with high pre-
HSCT decreased their anxiety levels during the post- HSCT,
while most of the ones with low anxiety remained the same.
Conclusions. Psychological assessment and preparation in-
creases the possibility of knowing variables that inﬂuence
the patient’s emotional status and create a treatment plan
appropriate for him/her.287
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Background: Since the inception of the pediatric transplant
program at the University of Mississippi Medical Center
(UMMC), intravenous gammaglobulin (IVIG) has been given
biweekly prophylactically post- transplant for up to 100 days
post transplantation. Many authors now report a lack of ef-
ﬁcacy in administering IVIG for this purpose and perhaps
adverse events such as infection, reaction, and even a higher
risk of veno-occlusive disease.
Methods: As a performance improvement project, a retro-
spective chart audit was completed to measure actual levels
of immunoglobulin G (IgG) in our transplant patients to see if
low levels of immunoglobulin G (IGG) could be identiﬁed.
Patients were characterized by age (at time of transplant),
